Bladder Cancer
1,083
187
259
470
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
163 trials with published results (15%)
Research Maturity
470 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.6%
104 terminated out of 1083 trials
81.9%
-4.6% vs benchmark
10%
108 trials in Phase 3/4
35%
163 of 470 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 470 completed trials
Clinical Trials (1083)
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
Measuring Surgical Recovery After Radical Cystectomy
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
Evaluation for NCI Surgery Branch Clinical Research Protocols
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer